Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease (Q41640163)

5 October 2017

Pioglitazone Prevents Diabetes in Patients With Insulin Resistance and Cerebrovascular Disease (English)

1 reference

5 October 2017

1 reference

Faramarz Ismail-Beigi

8

object named as

Faramarz Ismail-Beigi

1 reference

5 October 2017

7

Samuel Dagogo-Jack

1 reference

5 October 2017

2

Catherine M Viscoli

1 reference

5 October 2017

12

Walter N Kernan

1 reference

5 October 2017

4

Karen L Furie

1 reference

5 October 2017

5

Mark Gorman

1 reference

5 October 2017

6

Anne M Lovejoy

1 reference

5 October 2017

1

Silvio E Inzucchi

1 reference

5 October 2017

IRIS Trial Investigators

13

object named as

IRIS Trial Investigators

1 reference

5 October 2017

Lawrence H Young

3

1 reference

5 October 2017

Mary T Korytkowski

9

1 reference

5 October 2017

Richard E Pratley

10

1 reference

5 October 2017

Gregory G Schwartz

11

1 reference

5 October 2017

language of work or name

English

0 references

publication date

27 July 2016

1 reference

5 October 2017

1 reference

5 October 2017

39

1 reference

5 October 2017

1684-1692

1 reference

5 October 2017

10

1 reference

Pioglitazone use and risk of bladder cancer: population based cohort study

5 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Diabetes Incidence and Glucose Tolerance after Termination of Pioglitazone Therapy: Results from ACT NOW.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Pioglitazone after Ischemic Stroke or Transient Ischemic Attack

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Risk of hospitalization for heart failure in patients with type 2 diabetes newly treated with DPP-4 inhibitors or other oral glucose-lowering medications: a retrospective registry study on 127,555 patients from the Nationwide OsMed Health-DB Databas

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Determinants of adherence to diabetes medications: findings from a large pharmacy claims database

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

The peroxisome proliferator-activated receptors in cardiovascular diseases: experimental benefits and clinical challenges.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

We can change the natural history of type 2 diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Insulin resistance and hyperglycaemia in cardiovascular disease development

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Incidence of diabetes following ramipril or rosiglitazone withdrawal

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Insulin resistance, lipotoxicity, type 2 diabetes and atherosclerosis: the missing links. The Claude Bernard Lecture 2009

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Glucose meters: a review of technical challenges to obtaining accurate results

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Diagnosis and Classification of Diabetes Mellitus

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Skeletal muscle insulin resistance is the primary defect in type 2 diabetes

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trial

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

The prevention of type 2 diabetes mellitus.

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

PPARs in atherosclerosis: the clot thickens

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Thiazolidinedione use, fluid retention, and congestive heart failure: a consensus statement from the American Heart Association and American Diabetes Association

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Homeostasis model assessment: insulin resistance and ?-cell function from fasting plasma glucose and insulin concentrations in man

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Basal insulin and cardiovascular and other outcomes in dysglycemia

6 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Pioglitazone for diabetes prevention in impaired glucose tolerance.

6 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women

18 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5033078

2. Classification and Diagnosis of Diabetes

18 August 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27465265

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Diagnosis and classification of diabetes mellitus

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/27465265

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.2337/DC16-0798

1 reference

release_4vm4kkfsbzdxfpderomanl733q

5 October 2017

1 reference

Fatcat

https://api.fatcat.wiki/v0/release/4vm4kkfsbzdxfpderomanl733q

mapped directly with Wikidata item

24 November 2022

based on heuristic

1 reference

5 October 2017

1 reference